Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182027 | 0.86 | GRM5 (0.30) | GRM5 | |
| SCHEMBL235632 | 0.84 | MEN1 (0.30) | — | |
| SCHEMBL235633 | 0.84 | MEN1 (0.30) | — | |
| SCHEMBL10237444 | 0.83 | ALDH1A1 (0.36) | ACACBALDH1A1ALOX5EPHX2 | |
| SCHEMBL13916258 | 0.82 | — | — | |
| SCHEMBL13908053 | 0.80 | MEN1 (0.31) | — | |
| SCHEMBL237018 | 0.79 | KIF11 (0.32) | — | |
| SCHEMBL236218 | 0.78 | TAAR1 (0.41) | ACHE | |
| SCHEMBL235147 | 0.78 | TAAR1 (0.41) | — | |
| SCHEMBL232700 | 0.78 | ENPP2 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464033-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-11-19 | — | — | US | disclosed |
| US-9115056-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150045444-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-02-12 | — | — | US | disclosed |
| US-8895782-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140213617-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8766007-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8492589-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8389771-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130030026-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130018077-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8299307-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018077-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | GSK3B 1117/4885GRM5 4439/4885THRA 3666/4885 |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | PDE6D, STARD3, PDE6C | GSK3B 1117/4885GRM5 4439/4885THRA 3666/4885 |
| US-20130030026-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | GSK3B 1117/4885GRM5 4439/4885THRA 3666/4885 |
| US-20150045444-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | GSK3B 1117/4885GRM5 4439/4885THRA 3666/4885 |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, STARD3, PDE6C | GSK3B 1117/4885GRM5 4439/4885THRA 3666/4885 |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | GSK3B 1117/4885GRM5 4439/4885THRA 3666/4885 |
| US-20140213617-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | GSK3B 1117/4885GRM5 4439/4885THRA 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.